NCT00238628View on ClinicalTrials.gov

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

December 31, 2005

Conditions
Lung Cancer
Interventions
DRUG

Bexarotene

DRUG

Iressa

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors
All Listed Sponsors
collaborator

Ligand Pharmaceuticals

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Stanford University

OTHER